We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGHT icon
126
Sight Sciences
SGHT
$267M
$6.81M 0.07%
+300,000
New +$9.86M
LUNG icon
127
Pulmonx
LUNG
$49.4M
$6.35M 0.06%
176,510
– –
PRCT icon
128
Procept Biorobotics
PRCT
$950M
$5.72M 0.06%
+150,000
New +$5.76M
SYNH
129
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$4.99M 0.05%
57,000
-13,500
-19% -$1.22M
HRMY icon
130
Harmony Biosciences
HRMY
$2.04B
$4.96M 0.05%
+129,289
New +$4.16M
JNJ icon
131
Johnson & Johnson
JNJ
$635B
$4.93M 0.05%
30,500
-500
-2% -$85.3K
CTLT
132
DELISTED
CATALENT, INC.
CTLT
$4.79M 0.05%
36,000
+33,300
+1,233% +$4.16M
OLK
133
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$4.79M 0.05%
197,527
– –
SEER icon
134
Seer Inc
SEER
$108M
$4.7M 0.05%
136,133
– –
PFE icon
135
Pfizer
PFE
$140B
$4.28M 0.04%
+99,600
New +$4.41M
BMRN icon
136
BioMarin Pharmaceuticals
BMRN
$11.5B
$4M 0.04%
51,700
+11,200
+28% +$884K
BNTX icon
137
BioNTech
BNTX
$22.6B
$3.47M 0.04%
12,700
-9,900
-44% -$3.15M
MRTX
138
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.34M 0.03%
18,900
+11,600
+159% +$1.87M
NVAX icon
139
Novavax
NVAX
$1.23B
$3.32M 0.03%
+16,000
New +$3.53M
RCUS icon
140
Arcus Biosciences
RCUS
$3.57B
$3.3M 0.03%
94,700
+19,700
+26% +$613K
SNY icon
141
Sanofi
SNY
$104B
$3.23M 0.03%
67,000
-1,000
-1% -$50.8K
BCYC
142
Bicycle Therapeutics
BCYC
$270M
$2.73M 0.03%
+65,700
New +$2.3M
RARE icon
143
Ultragenyx Pharmaceutical
RARE
$2.65B
$2.52M 0.03%
27,900
+6,500
+30% +$588K
BHVN
144
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.43M 0.02%
17,500
-18,500
-51% -$2.31M
NTLA icon
145
Intellia Therapeutics
NTLA
$1.5B
$2.23M 0.02%
+16,594
New +$2.51M
CCCC icon
146
C4 Therapeutics
CCCC
$376M
$2.11M 0.02%
47,200
+16,200
+52% +$694K
KYMR icon
147
Kymera Therapeutics
KYMR
$9.1B
$2.08M 0.02%
+35,500
New +$2.06M
CDNA icon
148
CareDx
CDNA
$1.92B
$1.96M 0.02%
30,943
-117,928
-79% -$8.98M
ALLK
149
DELISTED
Allakos
ALLK
$1.96M 0.02%
18,500
– –
CVAC
150
DELISTED
CureVac
CVAC
$1.92M 0.02%
+35,200
New +$2.12M
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.